Activity of echinocandins and triazoles against a contemporary (2012) worldwide collection of yeast and moulds collected from invasive infections

International Journal of Antimicrobial Agents

Volumn 44, Issue 4, 2014, Pages 320-326

  Castanheira, Mariana ^a   Messer, Shawn A ^a   Jones, Ronald N ^a   Farrell, David J ^a   Pfaller, Michael A ^a  

^a JMI LABORATORIES   (United States)

Author keywords

Echinocandins; fks; Surveillance; Triazoles

Indexed keywords

ANTIFUNGAL AGENT; ECHINOCANDIN; TRIAZOLE DERIVATIVE;

DRUG EFFECTS; FUNGUS; HEALTH; HOSPITAL; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MYCOSIS;

ANTIFUNGAL AGENTS; ECHINOCANDINS; FUNGI; GLOBAL HEALTH; HOSPITALS; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOSES; TRIAZOLES;

EID: 84930334551     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2014.06.007     Document Type: Article

References (34)

1. G.D. Brown, D.W. Denning, N.A. Gow, S.M. Levitz, M.G. Netea, and T.C. White Hidden killers: human fungal infections Sci Transl Med 4 2012 165rv113
2. J. Menzin, J.L. Meyers, M. Friedman, D. Dixon, J.P. Marton, and J. Wilson Mortality, length of hospitalization, and costs associated with invasive fungal infections in high-risk patients Am J Health Syst Pharm 66 2009 1711 1717
3. M.C. Arendrup, E. Dzajic, R.H. Jensen, H.K. Johansen, P. Kjaeldgaard, and J.D. Knudsen Epidemiological changes with potential implication for antifungal prescription recommendations for fungaemia: data from a nationwide fungaemia surveillance programme Clin Microbiol Infect 19 2013 E343 E353
4. A.M. Borman, A. Szekely, M.D. Palmer, and E.M. Johnson Assessment of accuracy of identification of pathogenic yeasts in microbiology laboratories in the United Kingdom J Clin Microbiol 50 2012 2639 2644
5. M.A. Pfaller, S.A. Messer, L.N. Woosley, R.N. Jones, and M. Castanheira Echinocandin and triazole antifungal susceptibility profiles of opportunistic yeast and mould clinical isolates (2010-2011): application of new CLSI clinical breakpoints and epidemiological cutoff values to characterize geographic and temporal trends of antifungal resistance J Clin Microbiol 51 2013 2571 2581
6. J. Riddell, and C.A. Kauffman The evolution of resistant Candida species in cancer centers: implications for treatment and prophylaxis Cancer 112 2008 2334 2337
7. K.W. Garey, M. Rege, M.P. Pai, D.E. Mingo, K.J. Suda, and R.S. Turpin Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study Clin Infect Dis 43 2006 25 31
8. M. Kollef, S. Micek, N. Hampton, J.A. Doherty, and A. Kumar Septic shock attributed to Candida infection: importance of empiric therapy and source control Clin Infect Dis 54 2012 1739 1746
9. M.T. Fera, E. La Camera, and A. De Sarro New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance Expert Rev Anti Infect Ther 7 2009 981 998
10. M. Wilke Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin and its impact on use and costs: review of the literature Eur J Med Res 16 2011 180 186
11. B.D. Alexander, M.D. Johnson, C.D. Pfeiffer, C. Jiménez-Ortigosa, J. Catania, and R. Booker Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations Clin Infect Dis 56 2013 1724 1732
12. H.Y. Sun, and N. Singh Characterization of breakthrough invasive mycoses in echinocandin recipients: an evidence-based review Int J Antimicrob Agents 35 2010 211 218
13. L. Ostrosky-Zeichner Candida glabrata and FKS mutations: witnessing the emergence of the true multidrug-resistant Candida Clin Infect Dis 56 2013 1733 1734
14. M.A. Pfaller, L.N. Woosley, S.A. Messer, R.N. Jones, and M. Castanheira Significance of molecular identification and antifungal susceptibility of clinically significant yeasts and moulds in a global antifungal surveillance program Mycopathologia 174 2012 259 271
15. M.A. Pfaller, M. Castanheira, S.R. Lockhart, A.M. Ahlquist, S.A. Messer, and R.N. Jones Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata J Clin Microbiol 50 2012 1199 1203
16. J.W. van der Linden, E. Snelders, G.A. Kampinga, B.J. Rijnders, E. Mattsson, and Y.J. Debets-Ossenkopp Clinical implications of azole resistance in Aspergillus fumigatus, The Netherlands, 2007-2009 Emerg Infect Dis 17 2011 1846 1854
17. Clinical and Laboratory Standards Institute Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard. Document M27-A3 3rd ed. 2008 CLSI Wayne, PA
18. Clinical and Laboratory Standards Institute Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard. Document M38-A2 2nd ed. 2008 CLSI Wayne, PA
19. K.C. Hazen, and S.A. Howell Candida, Cryptococcus, and other yeasts of medical importance P.R. Murray, E.J. Baron, J.H. Jorgensen, M.L. Landry, M.A. Pfaller, Manual of clinical microbiology 2007 ASM Press Washington, DC 1762 1788
20. D.H. Larone Medically important fungi: a guide to identification 4th ed. 2002 ASM Press Washington, DC
21. M. Castanheira, L.N. Woosley, D.J. Diekema, R.N. Jones, and M.A. Pfaller Candida guilliermondii and other species of Candida misidentified as Candida famata: assessment by Vitek 2, DNA sequencing analysis, and matrix-assisted laser desorption ionization-time of flight mass spectrometry in two global antifungal surveillance programs J Clin Microbiol 51 2013 117 124
22. Clinical and Laboratory Standards Institute Reference method for broth dilution antifungal susceptibility testing of yeasts; third informational supplement. Document M27-S3 2008 CLSI Wayne, PA
23. Clinical and Laboratory Standards Institute Reference method for broth dilution antifungal susceptibility testing of yeasts; fourth informational supplement. Document M27-S4 2012 CLSI Wayne, PA
24. M.A. Pfaller, and D.J. Diekema Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012 J Clin Microbiol 50 2012 2846 2856
25. A. Espinel-Ingroff, A. Chowdhary, M. Cuenca-Estrella, A. Fothergill, J. Fuller, and F. Hagen Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for amphotericin B and flucytosine Antimicrob Agents Chemother 56 2012 3107 3113
26. A. Espinel-Ingroff, D.J. Diekema, A. Fothergill, E.M. Johnson, T. Pelaez, and M.A. Pfaller Wild-type MIC distributions and epidemiological cutoff values for the triazoles and six Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document) J Clin Microbiol 48 2010 3251 3257
27. J.L. Rodriguez-Tudela, L. Alcazar-Fuoli, E. Mellado, A. Alastruey-Izquierdo, A. Monzon, and M. Cuenca-Estrella Epidemiological cutoffs and cross-resistance to azole drugs in Aspergillus fumigatus Antimicrob Agents Chemother 52 2008 2468 2472
28. G. Garcia-Effron, S. Lee, S. Park, J.D. Cleary, and D.S. Perlin Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-β-d-glucan synthase: implications for the existing susceptibility breakpoint Antimicrob Agents Chemother 53 2009 3690 3699
29. M.C. Arendrup, D.S. Perlin, R.H. Jensen, S.J. Howard, J. Goodwin, and W. Hope Differential in vivo activity of anidulafungin, caspofungin and micafungin against Candida glabrata with and without FKS resistance mutations Antimicrob Agents Chemother 56 2012 2435 2442
30. E. Dannaoui, M. Desnos-Ollivier, D. Garcia-Hermoso, F. Grenouillet, S. Cassaing, and M.T. Baixench Candida spp. with acquired echinocandin resistance, France, 2004-2010 Emerg Infect Dis 18 2012 86 90
31. R.K. Shields, M.H. Nguyen, E.G. Press, A.L. Kwa, S. Cheng, and C. Du The presence of an FKS mutation rather than MIC is an independent risk factor for failure of echinocandin therapy among patients with invasive candidiasis due to Candida glabrata Antimicrob Agents Chemother 56 2012 4862 4869
32. Y.L. Yang, Y.A. Ho, H.H. Cheng, M. Ho, and H.J. Lo Susceptibilities of Candida species to amphotericin B and fluconazole: the emergence of fluconazole resistance in Candida tropicalis Infect Control Hosp Epidemiol 25 2004 60 64
33. S.R. Lockhart, J.P. Frade, K.A. Etienne, M.A. Pfaller, D.J. Diekema, and S.A. Balajee Azole resistance in Aspergillus fumigatus isolates from the ARTEMIS global surveillance study is primarily due to the TR/L98H mutation in the cyp51A gene Antimicrob Agents Chemother 55 2011 4465 4468
34. E. Snelders, H.A. van der Lee, J. Kuijpers, A.J. Rijs, J. Varga, and R.A. Samson Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism PLoS Med 5 2008 e219